Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
about
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingSubcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Lupus nephritis and B-cell targeting therapy.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Belimumab in the management of systemic lupus erythematosus - an update.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Novel Treatments in Lupus.Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.B Cell-Based Treatments in SLE: Past Experience and Current Directions.Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.An era of biological treatment in systemic lupus erythematosus.Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials.Systemic lupus erythematosus and ocular involvement: an overview.Lupus community panel proposals for optimising clinical trials: 2018.New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
P2860
Q33691812-442468E3-8136-4F1D-9B30-BC0A8A0DFA73Q38605480-51896023-CCDE-4557-8269-613C802BBAB9Q38643755-D0BA0D4C-01FA-45BC-A8D2-2510441742F2Q38690844-B5D84FFA-FA15-402A-9CDA-A744E8C743D7Q38810737-2AACB418-E69F-425B-B282-4987291270A5Q39150632-343FFED3-EB8D-491E-90BC-13386FE3F361Q39164953-97183444-7ABC-4B6A-B17B-D875C4F7A9CDQ47552016-5D666215-E79D-44D1-8A54-F26C159F11B8Q47660691-D2DF95C4-591A-402C-89CF-1894DB04AD8CQ47709719-82D61E64-FDFF-4152-8B7B-DD96377B9D58Q48128911-D1A51757-5469-401E-BCEF-FA52EA182416Q49577334-32EAC310-24FA-437E-8CBE-BB9BC2C030A1Q49833678-450AAFD3-339D-4FA1-9A2F-39847019D354Q52320880-F3B93910-6832-445E-B802-BBF65ECB2CF9Q53383480-2F518A4C-C23A-4EB1-A88F-5EA27D97190EQ57490095-4E17BB8B-049C-40FD-BFDB-F0D6E3C47618
P2860
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@en
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@nl
type
label
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@en
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@nl
prefLabel
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@en
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@nl
P2093
P2860
P356
P1476
Efficacy and Safety of Epratuz ...... nd, Placebo-Controlled Trials.
@en
P2093
Brian Kilgallen
C Michael Neuwelt
Carolyn Beaudot
Catrinel Galateanu
Christian Stach
Daniel J Wallace
EMBODY Investigator Group
Kathryn Hobbs
Kenneth C Kalunian
Liliana Duca
P2860
P304
P356
10.1002/ART.39856
P577
2016-09-06T00:00:00Z